Quantitative analysis of t-wave morphology increases confidence in drug-induced cardiac repolarization abnormalities: Evidence from the investigational ikr inhibitor lu 35-138

Journal of Clinical Pharmacology

Volumn 49, Issue 11, 2009, Pages 1331-1342

  Graff, Claus ^a   Matz, Joørgen ^b   Christensen, Ellen B ^b   Andersen, Mads P ^a   Kanters, Joørgen K ^c,d,e   Toft, Egon ^a,e   Pehrson, Steen ^f   Hardahl, Thomas B ^a   Nielsen, Jimmi ^e   Struijk, Johannes J ^a  

^a AALBORG UNIVERSITY   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f Rigshospitalet   (Denmark)

Author keywords

Drugs; ECG; QT interval; Repolarization; T wave morphology

Indexed keywords

LU 35 138; NEUROLEPTIC AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG INHIBITION; ELECTROCARDIOGRAM; FEMALE; HEART REPOLARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; QT INTERVAL; QUANTITATIVE ANALYSIS; T WAVE;

ADOLESCENT; ADULT; DELAYED RECTIFIER POTASSIUM CHANNELS; DIHYDROPYRIDINES; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; INDOLES; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR;

EID: 70350432728     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009344853     Document Type: Article

References (39)

1. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002 ; 287: 2215-2220.
2. Fermini B., Fossa AA The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov. 2003 ; 2: 439-447.
3. De Ponti F., Poluzzi E., Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 2000 ; 56: 1-18.
4. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview. Drug Safety. 2002 ; 25: 263-286.
5. Shah RR The significance of QT interval in drug development. Br J Clin Pharmacol. 2002 ; 54: 188-202.
6. Roden DM Drug induced prolongation of the QT interval. N Engl J Med. 2004 ; 350: 1013-1022.
7. Guidance for Industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005. http://www.fda.gov/cber/gdlns/iche14qtc.pdf. Accessed March 16, 2009.
8. Hutmacher MM, Chapel S., Agin MA, Fleishaker JC, Lalonde RL Performance characteristics for some typical QT study designs under the ICH E-14 guidance. J Clin Pharmacol. 2008 ; 48: 215-224.
9. Patterson S., Agin M., Anziano R., et al. Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations. Report from the pharmaceutical research and manufacturers of America QT statistics expert team. Drug Inf J. 2005 ; 39: 243-266.
10. Malik M. The Imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol. 2002 ; 25: 209-216.
11. Hinkelmann K., Kempthorne O. Design and Analysis of Experiments, Volume 1: Introduction to Experimental Design. New York, NY: Wiley and Sons ; 1994.
12. Zhou SH, Wong S., Rautaharju PM, Karnik N., Calhoun HP Should the JT rather than the QT interval be used to detect prolongation of ventricular repolarization? An assessment in normal conduction and in ventricular conduction defects. J Electrocardiol. 1992 ; 25 (suppl): 131-136.
13. Haverkamp W., Breithart G., Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Eur Heart J. 2000 ; 21 ; 1216-1230.
14. Hoffmann P., Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxcicol Methods. 2006 ; 53: 87-105.
15. Sanguinetti MC, Curran ME, Spector PS, Keating MT Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci U S A. 1996 ; 93: 2208-2212.
16. Graff C., Andersen MP, Xue JQ, et al. Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology. Drug Safety. 2009 ; 32: 599-611.
17. Nielsen J., Graff C., Hardahl T., et al. Sertindole causes distinct electrorcardiographic T-wave morphology changes. Eur Neuropsychopharmacol. 2009 ; 19: 702-707.
18. Lehmann MH, Suzuki F., Fromm BS, et al. T wave "humps" as a potential electrocardiographic marker of the long-QT syndrome. J Am Coll Cardiol. 1994 ; 24: 746-754.
19. Malfatto G., Beria G., Sala S., Bonazzi O., Schwartz PJ Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long-QT syndrome. J Am Coll Cardiol. 1994 ; 23: 296-301.
20. Lupoglazoff JM, Denjoy I., Berthet M., et al. Notched T waves on Holter recordings enhance detection of patients with LQT2 (HERG) mutations. Circulation. 2001 ; 103: 1095-1101.
21. Merri M., Benhorin J., Alberti M., Locati E., Moss AJ Electrocardiographic quantitation of ventricular repolarization. Circulation. 1989 ; 80: 1301-1308.
22. Benhorin J., Merri M., Alberti M., et al. Long QT syndrome: new electrocardiographic characteristics. Circulation. 1990 ; 82: 521-527.
23. Struijk JJ, Kanters JK, Andersen MP, et al. Classification of the long QT syndrome based on discriminant analysis of T-wave morphology. Med Biol Eng Comput. 2006 ; 44: 543-549.
24. Gima K., Rudy Y. Ionic current basis of electrocardiographic waveforms: a model study. Circ Res. 2002 ; 90: 889-896.
25. Shah RR, Hondeghem LM Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm. 2005 ; 2: 758-772.
26. Antzelevitch C. Heterogeneity of cellular repolarization in LQTS: the role of M cells. Eur Heart J Suppl. 2001 ; 3 (suppl K). K2 - K16.
27. Andersen MP, Xue JQ, Graff C., et al. Robust method for quantification of Ikr-related T-wave morphology abnormalities. Comput Cardiol. 2007 ; 34: 341-344.
28. Andersen MP, Xue JQ, Graff C., et al. New descriptors of T-wave morphology are independent of heart rate. J Electrocardiol. 2008 ; 41: 557-561.
29. Glass GV Integrating findings: the meta-analysis of research. Rev Res Educ. 1997 ; 5: 351-379.
30. Bland JM, Altman DG Statistics notes: measurement error. BMJ. 1996 ; 313: 744.
31. Chow SC, Cheng B., Cosmatos D. On power and sample size calculation with recording replicates at given time point. J Biopharm Stat. 2008 ; 18: 483-493.
32. Topilski I., Rogowski O., Rosso R., et al. The morphology of the QT interval predicts Torsade de Pointes during acquired bradyarrhythmias. J Am Coll Cardiol. 2007 ; 49: 320-328.
33. Debbas NMG, du Cailar C., Bexton RS, Demaille JG, Camm AJ, Puech P. The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J. 1984 ; 51: 316-320.
34. van Opstal JM, Schoenmakers M., Verduyn C., et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001 ; 104: 2722-2727.
35. Malik M, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol. 2004;27:1659-1669. 36.
36. Berger RD. QT variability. J Electrocardiol. 2003;36(suppl): 83-87.
37. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001 ; 12: 411-420.
38. Malik M., Camm AJ Evaluation of drug-induced QT interval prolongation. Drug Safety. 2001 ; 24: 323-351.
39. Couderc JP, McNitt S., Hyrien O., et al. Improving the detection of subtle IKr-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin. Drug Safety. 2008 ; 31: 249-260.